Navigation Links
PAREXEL Appoints Leading Central Nervous System Experts to Its Global Clinical Pharmacology Business
Date:4/2/2008

BOSTON, April 2, 2008 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services organization, today announced that Larry Ereshefsky, Pharm.D., F.C.C.P., B.C.C.P., and Malek Bajbouj, M.D., have been appointed as Vice Presidents of Clinical Pharmacology Consulting Services in the Company's international clinical pharmacology business. These leading experts advise clients on early phase clinical development in the central nervous system (CNS) therapeutic area, including in regard to psychiatry, neuropsychopharmacology, and neurophysiology clinical studies. Dr. Ereshefsky is based at PAREXEL's Clinical Pharmacology Research Unit in Los Angeles, California in the United States and Dr. Bajbouj is based at the unit in Berlin, Germany.

"Clients increasingly rely on our experts to help identify and select the most promising compounds in the Phase I and Proof of Concept stages. These decisions are based on demonstrating safety and signals of efficacy as early as possible in the drug development process," said Herman Scholtz, M.D., Corporate Vice President and Worldwide Head, Clinical Pharmacology, PAREXEL. "We expect that the extensive medical and scientific expertise Dr. Ereshefsky and Dr. Bajbouj bring to our clinical pharmacology business will further strengthen our central nervous system capabilities in order to help biopharmaceutical companies address growing complexity in this important area of early phase clinical development."

Dr. Larry Ereshefsky is Board Certified in Psychiatric Pharmacy, and has more than 28 years of experience in the neuropsychopharmacology and psychiatry fields. His expertise includes all phases of clinical research and psychopharmacological ev
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France
2. PAREXEL Announces Date of Third Quarter Fiscal Year 2008 Earnings Release and Conference Call
3. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
4. PAREXEL International to Present at Lehman Brothers 11th Annual Global Healthcare Conference
5. PAREXEL International to Present at Raymond James 29th Annual Institutional Investors Conference
6. PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting
7. PAREXEL International Announces 2-For-1 Stock Split
8. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
9. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
10. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
11. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...FirstCall/ -- AstraZeneca (NYSE:,AZN) today announ...A) has,approved once-daily SEROQUEL XR(R) (quetiap...te treatment of the depressive episodes associated...es associated with bipolar I,disorder, and the mai...tive,therapy to lithium or divalproex. SEROQUEL XR...
(Date:10/10/2008)...Takeda Pharmaceutical Company,Limited ("Takeda") t...elopment Center, Inc., a wholly owned United State...e U.S. Food and Drug Administration (FDA) will,not...New Drug Application,(NDA) by the Prescription Dru... "In our most recent discussion with the FDA, it i...
(Date:10/9/2008)...up six spots from last year, ST. LOUIS, Oct. 9 /P...N) is earning recognition as a leader in biotechno... also for being a great place to work., Monsanto,... place in,the 2008 Top Biotech and Pharma Employer... The company moved up six spots from number eight ...
(Date:10/9/2008)... - Dr. Brad Thompson, President,and CEO of Oncolyt...esent a,corporate overview of the Company at the 1...on, U.K. on Monday, October 13 at 2 p.m. The confe...nference Centre from October,12-14, 2008., About ...based biotechnology company focused on the,develop...
Breaking Biology Technology:FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 2FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 3FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 4FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 5FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 6FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 7FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 8FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 9FDA Continues Review of Takeda's New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes 2Monsanto Recognized as Top Biotechnology Employer by Science Magazine 2Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe 2
... stories to tell, but perhaps nothing is more illu...ory of a little girl drawing in the back of a clas...ul Getty Trust in Los Angeles and an internationa..., told the story during a keynote address at the a...Association Conference. , ,Noting that young chil...
...ago Bar Association entitled "Communication Rights...t Century." At that time, many who attended thou...faith in it. My argument was that the horse-and-bu...d liquor were maxed out. Municipalities would have...ms that could pay for services and pensions. , ,Th...
...n Internet data provider, has appointed its legal ...ions officer. , ,Meier brings experience in the le...and he will be responsible for helping the Milwauk...and business development programs. , ,"I believe i...go when it was just two people and an idea," Donat...
...and his company through a series of mergers and pe...der of JT Packard & Associates, Inc. , Cason pres...er. The company has grown by 500 percent over the ...ptible power supply (UPS) service company in the c...,With its recent purchase by Anaheim, Calif.-based...
Other Biology Technology:Sir Ken Robinson: Companies, kids "get" innovation, but K-12 doesn't nurture it 2Sir Ken Robinson: Companies, kids "get" innovation, but K-12 doesn't nurture it 3Creativity, innovation extend to municipalities 2Creativity, innovation extend to municipalities 3Creativity, innovation extend to municipalities 4Power services firm JT Packard isn't through growing 2Power services firm JT Packard isn't through growing 3
(Date:10/10/2008)...ry researchers have found that statins may be able...g from pregnancy complications caused by antiphosp...ce. In this autoimmune syndrome, the body produces...mponents of cell membranes. This news comes from a...nal of Clinical Investigation that is currently o...
(Date:10/10/2008)...f Kyoto University and the Gladstone Institute of ...ep forward in improving the possibilities for the ...(iPS) cell technology. , Previously, Dr. Yamanak...o become embryonic stem celllike using a cancer-ca...o reprogram the cells, and a virus to transfer the...
(Date:10/10/2008)..., Gasterosteus aculeatus , is one of the most tho...n a particularly useful model for understanding va...morphology caused by different ecological situatio...cular and genetic to developmental and morphologic...it has proven far more complex than even imagined....
(Date:10/10/2008)... in German . , DNA, the molecule that acts as...f life, is highly resistant against alteration by ... for its photostability presents some puzzling pro... four chemical bases that make up the DNA molecule... showing that DNA strands differ in their light se...
Breaking Biology News(10 mins):Statins may prevent miscarriages 2Statins may prevent miscarriages 3Yamanaka eliminates viral vector in stem cell reprogramming 2Fitness in a changing world 2Fitness in a changing world 3Can genetic information be controlled by light? 2Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases 1932 1Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases 1932 2Engineers harness cell phone technology for use in medical imaging 4950 1Engineers harness cell phone technology for use in medical imaging 4950 2Engineers harness cell phone technology for use in medical imaging 4950 3Engineers harness cell phone technology for use in medical imaging 4950 4Viscosity Enhancers Curb Bleeding Complications 17971 1Viscosity Enhancers Curb Bleeding Complications 17971 2Genes Linked to Osteoporosis Identified 17967 1Genes Linked to Osteoporosis Identified 17967 2Genes Linked to Osteoporosis Identified 17967 3
...f Medicine researchers have discovered how new neu...nt to regions of the brain where they can replace ...tem cell therapies can be specifically targeted to...ses or by stroke. , Associate Professor Qun-Yong Z...artment of Pharmacology have identified a protein ...
... the world are breathing a sigh of relief, as they...ir natural disease-fighting substances. Scientists... didemnii, which lives symbiotically inside the se...es, compounds that may one day be used in cancer t...s could not successfully cultivate Prochloron in t...
...sma protein found in blood, can be fused with larg...stimulating factor (G-CSF) to create a new oral co...rough the gastrointestinal (GI) tract and then abl... the body, according to research from the Universi...is technology may allow for oral administration of...
...factors prove that BioMed Central,s Open Access jo... Journals published by BioMed Central have again r...valent subscription titles, it was announced today...lty. The high impact factors for these journals af...re fast becoming the place for authors to submit i...
Other Biology News:Researchers discover stem cell 'guide' that may be key for targeting neural stem cell treatments 2Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs 2Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs 3'Bionic' arm gives amputee sense of touch 2
...itivity Laboratory Osmometer for both 0.2 and 2.0 ...ludes built-in printer, keypad, and software for s...reading capability with optional scanner. RS-232 p...Two-step Calibration. ...
MAb to Hu-IFN-Gamma RC2 (CD118), NON-Neutralizing, Clone MMHGR-2 Binds to but does not neutralize human interferon gamma receptor
Recombinant Rat CINC-2 alpha, CF
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice
Biology Products: